Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

1.

Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion.

Ferguson J, Arozarena I, Ehrhardt M, Wellbrock C.

Oncogene. 2013 Jan 3;32(1):86-96. doi: 10.1038/onc.2012.25. Epub 2012 Feb 6.

PMID:
22310287
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells.

El Touny LH, Vieira A, Mendoza A, Khanna C, Hoenerhoff MJ, Green JE.

J Clin Invest. 2014 Jan 2;124(1):156-68. doi: 10.1172/JCI70259. Epub 2013 Dec 9.

PMID:
24316974
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.

Yang JC, Bai L, Yap S, Gao AC, Kung HJ, Evans CP.

Mol Cancer Ther. 2010 Jun;9(6):1629-37. doi: 10.1158/1535-7163.MCT-09-1058. Epub 2010 May 18.

PMID:
20484016
[PubMed - indexed for MEDLINE]
Free Article
4.

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.

Holt SV, LogiƩ A, Odedra R, Heier A, Heaton SP, Alferez D, Davies BR, Wilkinson RW, Smith PD.

Br J Cancer. 2012 Feb 28;106(5):858-66. doi: 10.1038/bjc.2012.8. Epub 2012 Feb 16.

PMID:
22343622
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma.

Smith MP, Ferguson J, Arozarena I, Hayward R, Marais R, Chapman A, Hurlstone A, Wellbrock C.

J Natl Cancer Inst. 2013 Jan 2;105(1):33-46. doi: 10.1093/jnci/djs471. Epub 2012 Dec 17.

PMID:
23250956
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles.

Aftimos PG, Wiedig M, Langouo Fontsa M, Awada A, Ghanem G, Journe F.

Int J Oncol. 2013 Sep;43(3):919-26. doi: 10.3892/ijo.2013.2008. Epub 2013 Jul 8.

PMID:
23835698
[PubMed - indexed for MEDLINE]
7.

Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.

Ambrosini G, Pratilas CA, Qin LX, Tadi M, Surriga O, Carvajal RD, Schwartz GK.

Clin Cancer Res. 2012 Jul 1;18(13):3552-61. doi: 10.1158/1078-0432.CCR-11-3086. Epub 2012 May 1.

PMID:
22550165
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death.

Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P.

Cancer Biol Ther. 2011 Aug 1;12(3):215-28. Epub 2011 Aug 1.

PMID:
21642769
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.

Bai L, Yang JC, Ok JH, Mack PC, Kung HJ, Evans CP.

Int J Cancer. 2012 Jun 1;130(11):2693-702. doi: 10.1002/ijc.26303. Epub 2011 Sep 14.

PMID:
21792888
[PubMed - indexed for MEDLINE]
10.

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells.

Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, Davies MA.

Cancer Res. 2010 Nov 1;70(21):8736-47. doi: 10.1158/0008-5472.CAN-10-0902. Epub 2010 Oct 19.

PMID:
20959481
[PubMed - indexed for MEDLINE]
Free Article
11.

Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling.

Huntington JT, Shields JM, Der CJ, Wyatt CA, Benbow U, Slingluff CL Jr, Brinckerhoff CE.

J Biol Chem. 2004 Aug 6;279(32):33168-76. Epub 2004 Jun 7.

PMID:
15184373
[PubMed - indexed for MEDLINE]
Free Article
12.

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.

Gangadhar TC, Clark JI, Karrison T, Gajewski TF.

Invest New Drugs. 2013 Jun;31(3):769-73. doi: 10.1007/s10637-012-9897-4. Epub 2012 Nov 15.

PMID:
23151808
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.

Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M, Smalley KS.

Clin Cancer Res. 2008 Jan 1;14(1):230-9. doi: 10.1158/1078-0432.CCR-07-1440.

PMID:
18172275
[PubMed - indexed for MEDLINE]
Free Article
14.

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.

Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V.

Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7248-55. doi: 10.1167/iovs.11-7398.

PMID:
21828154
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells.

Purnell PR, Mack PC, Tepper CG, Evans CP, Green TP, Gumerlock PH, Lara PN, Gandara DR, Kung HJ, Gautschi O.

J Thorac Oncol. 2009 Apr;4(4):448-54. doi: 10.1097/JTO.0b013e31819c78fb.

PMID:
19240653
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines.

Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, Li L, Gimotty PA, Wilson M, Hayden J, Keeney F, Nathanson KL, Herlyn M.

Oncogene. 2014 Apr 3;33(14):1850-61. doi: 10.1038/onc.2013.131. Epub 2013 Apr 29.

PMID:
23624919
[PubMed - indexed for MEDLINE]
17.

MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.

Bartholomeusz C, Oishi T, Saso H, Akar U, Liu P, Kondo K, Kazansky A, Krishnamurthy S, Lee J, Esteva FJ, Kigawa J, Ueno NT.

Mol Cancer Ther. 2012 Feb;11(2):360-9. doi: 10.1158/1535-7163.MCT-11-0400. Epub 2011 Dec 5.

PMID:
22144664
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).

Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD.

Cancer Res. 2010 Mar 15;70(6):2264-73. doi: 10.1158/0008-5472.CAN-09-1577. Epub 2010 Mar 9.

PMID:
20215513
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.

Nam HJ, Im SA, Oh DY, Elvin P, Kim HP, Yoon YK, Min A, Song SH, Han SW, Kim TY, Bang YJ.

Mol Cancer Ther. 2013 Jan;12(1):16-26. doi: 10.1158/1535-7163.MCT-12-0109. Epub 2012 Nov 9.

PMID:
23144237
[PubMed - indexed for MEDLINE]
Free Article
20.

Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.

Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E, Schwartz GK.

PLoS One. 2012;7(7):e40439. doi: 10.1371/journal.pone.0040439. Epub 2012 Jul 10.

PMID:
22808163
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk